USPSTF No Longer Recommends Aspirin Prophylaxis for Colorectal Cancer, CVD
The new guidelines say there is insufficient evidence to support using aspirin to reduce colorectal cancer incidence or mortality.
The new guidelines say there is insufficient evidence to support using aspirin to reduce colorectal cancer incidence or mortality.
An interviews conducted with patients and caregivers demonstrated the effects of an early palliative care pathway for advanced colorectal cancer.
The most common complementary medicines were herbal/natural products, dietary supplements, fish oils, glucosamine, and homeopathic medicines.
The excess risk of cancer appeared to be associated with the severity of heart failure.
Overall survival data were available for about half of the drugs.
Investigators assessed rates of colorectal cancer screening participation in the time periods before and after introduction of multi-target stool DNA tests.
There was a significant increase in out-of-pocket costs for all 4 cancer types studied.
The study showed no significant differences in outcomes by age.
About 31% of the articles analyzed contained information classified as harmful.
Phase 3 results refute findings from retrospective studies.